Neurocrine Biosciences | Los Gastos Financieros De La Deuda



Interest Expense On Debt Cambio Fecha
AbbVie USD 610M 19M 2024-12
Agios Pharmaceuticals 3.01M 10.05M 2024-12
ALKERMES USD 4.65M 1.35M 2024-12
Alnylam Pharmaceuticals USD 38.97M 4.6M 2024-12
Amgen USD 747M 29M 2024-12
Biogen USD 60M 200K 2024-12
BioMarin Pharmaceutical USD 2.58M 391K 2024-12
Cytokinetics USD 22.59M 296K 2024-12
Dynavax Technologies USD 1.7M 5K 2024-12
Exelixis 23.4M 3.9M 2023-09
Gilead Sciences USD 248M 10M 2024-12
Halozyme Therapeutics USD 4.54M 16K 2024-12
Incyte USD 419K 355K 2024-12
Ionis Pharmaceuticals USD 2.59M 70K 2024-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 739M 45M 2024-12
Prothena 0 0 2024-06
Regeneron Pharmaceuticals USD 10.5M 3.3M 2024-12
Repligen USD 5.46M 88K 2024-12
Sarepta Therapeutics USD 4.92M 86K 2024-09
Teva Pharmaceutical Industries USD 224M 1000K 2024-12
Ultragenyx Pharmaceutical 15.52M 190K 2024-12
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



Neurocrine Biosciences Los Gastos Financieros De La Deuda - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.